Utlysning - söker patienter med atopiskt eksem för intervju
Vi på TIRmed samarbetar tillsammans med Atopikerna för en patientundersökning. TIRmed Pharma håller just nu på att utveckla en ny kräm...
Contact us
News
- 17 maj
TIR-C selected for IVA's 100 list
TIRmed Pharma's project to developing TIR-C has been listed by Kungliga IngenjörsVetenskapsakademien (IVA) in their annual 100 list as...
- 27 apr.
TIRmed Pharma consortium receives grant of 1.5 MSEK from Vinnova
Vinnova, together with Swelife and Medtech4health, have jointly called for new innovative projects within life science and medical...
- 12 sep. 2021
TIRmed Pharma initiates permeability study with leading CRO
TIRmed Pharma have begun a permeability study on their cream targeting Atopic Dermatitis, TIR-C. The study will showcase its ability to...
- 20 nov. 2020
TIRmed Pharma raises 5.4 MSEK in equity for pre-clinical development
Eczema is a common disease affecting up to 20% of children and approximately 3% of adults, with a drugs market estimated up to 75 BSEK...
- 15 okt. 2020
New publication
Amelioration of Compound 48/80-Mediated Itch and LL-37-Induced Inflammation by a Single-Stranded Oligonucleotide Authors: Aleksandra...
- 17 juni 2020
- 11 maj 2020
TIRmed Pharma receives approval of patent in the US
TIRmed Pharma´s proprietary compound to treat inflammatory skin disorders was issued patent approval in the US, April 21st, 2020.
Contact information
TIRmed Pharma AB
559149-0213
Alviksvägen 1, 167 53 Stockholm